Allovir IncNASDAQ:ALVRNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7233
- TODAY'S CHANGE (%)-0.0567 (-7.2692%)
- Bid / Lots0.7200/ 10
- Ask / Lots0.7800/ 8
- Open / Previous Close0.7796 / 0.7800
- Day Range
- 52 Week Range
- Volume6,206,421
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALVR |
|---|---|---|
| 09:32 ET | 649 | 0.7796 |
| 09:41 ET | 139 | 0.7506 |
| 09:43 ET | 100 | 0.78 |
| 09:52 ET | 500 | 0.78 |
| 09:54 ET | 432 | 0.7651 |
| 09:56 ET | 200 | 0.76525 |
| 09:57 ET | 200 | 0.76525 |
| 09:59 ET | 500 | 0.78 |
| 10:10 ET | 220 | 0.78 |
| 10:15 ET | 1526 | 0.7797 |
| 10:17 ET | 1545 | 0.7796 |
| 10:21 ET | 2560 | 0.76535 |
| 10:26 ET | 300 | 0.76535 |
| 10:28 ET | 1438 | 0.76535 |
| 10:30 ET | 534 | 0.76535 |
| 10:32 ET | 1763 | 0.7796 |
| 10:33 ET | 500 | 0.7656 |
| 10:35 ET | 3206 | 0.7797 |
| 10:37 ET | 1600 | 0.7656 |
| 10:39 ET | 551 | 0.7795 |
| 10:42 ET | 1212 | 0.7796 |
| 10:44 ET | 2422 | 0.76535 |
| 10:46 ET | 800 | 0.76535 |
| 10:48 ET | 1861 | 0.76535 |
| 10:50 ET | 1356 | 0.7796 |
| 10:51 ET | 700 | 0.7795 |
| 10:53 ET | 1562 | 0.7699 |
| 10:55 ET | 740 | 0.7795 |
| 10:57 ET | 1300 | 0.7698 |
| 11:00 ET | 1100 | 0.7705 |
| 11:02 ET | 1007 | 0.7706 |
| 11:04 ET | 1160 | 0.77025 |
| 11:06 ET | 300 | 0.77025 |
| 11:08 ET | 400 | 0.761 |
| 11:09 ET | 200 | 0.7793 |
| 11:11 ET | 300 | 0.779 |
| 11:13 ET | 628 | 0.761 |
| 11:15 ET | 3025 | 0.7784 |
| 11:20 ET | 400 | 0.77025 |
| 11:22 ET | 500 | 0.77025 |
| 11:24 ET | 100 | 0.7702 |
| 11:26 ET | 2375 | 0.77025 |
| 11:27 ET | 100 | 0.763 |
| 11:29 ET | 6186 | 0.77025 |
| 11:31 ET | 4206 | 0.77025 |
| 11:33 ET | 1085 | 0.761 |
| 11:36 ET | 600 | 0.762 |
| 11:38 ET | 2573 | 0.762 |
| 11:40 ET | 2266 | 0.7662 |
| 11:42 ET | 1203 | 0.7662 |
| 11:44 ET | 522 | 0.7662 |
| 11:45 ET | 641 | 0.7714 |
| 11:47 ET | 740 | 0.7662 |
| 11:49 ET | 708 | 0.7714 |
| 11:51 ET | 3712 | 0.761 |
| 11:54 ET | 598 | 0.7714 |
| 11:56 ET | 921 | 0.7662 |
| 11:58 ET | 405 | 0.7613 |
| 12:00 ET | 1917 | 0.7662 |
| 12:03 ET | 739 | 0.7662 |
| 12:05 ET | 743 | 0.761 |
| 12:09 ET | 4458 | 0.7662 |
| 12:14 ET | 1054 | 0.7662 |
| 12:16 ET | 416 | 0.7662 |
| 12:18 ET | 950 | 0.767 |
| 12:20 ET | 1782 | 0.7733 |
| 12:21 ET | 893 | 0.7791 |
| 12:23 ET | 400 | 0.7852 |
| 12:25 ET | 595 | 0.7852 |
| 12:27 ET | 847 | 0.7857 |
| 12:30 ET | 132 | 0.78 |
| 12:32 ET | 508 | 0.7857 |
| 12:34 ET | 200 | 0.7794 |
| 12:36 ET | 1460 | 0.7856 |
| 12:38 ET | 2595 | 0.7828 |
| 12:39 ET | 493 | 0.7828 |
| 12:41 ET | 3681 | 0.7748 |
| 12:43 ET | 2443 | 0.7691 |
| 12:45 ET | 200 | 0.7671 |
| 12:48 ET | 3058 | 0.7642 |
| 12:50 ET | 609 | 0.76415 |
| 12:52 ET | 800 | 0.761 |
| 12:54 ET | 800 | 0.761 |
| 12:56 ET | 100 | 0.761 |
| 12:57 ET | 1036 | 0.7611 |
| 12:59 ET | 464 | 0.7611 |
| 01:01 ET | 1545 | 0.7601 |
| 01:03 ET | 1300 | 0.7601 |
| 01:06 ET | 800 | 0.7601 |
| 01:10 ET | 237 | 0.7622 |
| 01:12 ET | 300 | 0.7601 |
| 01:14 ET | 3176 | 0.7622 |
| 01:15 ET | 1200 | 0.7612 |
| 01:17 ET | 995 | 0.7602 |
| 01:19 ET | 1282 | 0.7602 |
| 01:21 ET | 1214 | 0.7601 |
| 01:24 ET | 907 | 0.7601 |
| 01:26 ET | 520 | 0.7602 |
| 01:28 ET | 635 | 0.7604 |
| 01:30 ET | 300 | 0.7602 |
| 01:32 ET | 376 | 0.7602 |
| 01:33 ET | 794 | 0.7622 |
| 01:35 ET | 800 | 0.7633 |
| 01:37 ET | 400 | 0.7614 |
| 01:39 ET | 243 | 0.7633 |
| 01:42 ET | 1580 | 0.7618 |
| 01:44 ET | 425 | 0.7645 |
| 01:46 ET | 2200 | 0.7615 |
| 01:48 ET | 1830 | 0.7614 |
| 01:50 ET | 1075 | 0.76 |
| 01:51 ET | 300 | 0.7577 |
| 01:53 ET | 1300 | 0.7528 |
| 01:55 ET | 421 | 0.7502 |
| 01:57 ET | 5051 | 0.747 |
| 02:00 ET | 20950 | 0.7496 |
| 02:02 ET | 6420 | 0.74895 |
| 02:04 ET | 4647 | 0.7512 |
| 02:06 ET | 100 | 0.7555 |
| 02:08 ET | 4205 | 0.75575 |
| 02:09 ET | 1727 | 0.75655 |
| 02:11 ET | 2471 | 0.7573 |
| 02:13 ET | 1249 | 0.7607 |
| 02:15 ET | 2312 | 0.7622 |
| 02:18 ET | 845 | 0.7629 |
| 02:20 ET | 600 | 0.7629 |
| 02:22 ET | 700 | 0.7653 |
| 02:24 ET | 700 | 0.7688 |
| 02:26 ET | 588 | 0.7688 |
| 02:27 ET | 100 | 0.7623 |
| 02:29 ET | 1952 | 0.7616 |
| 02:31 ET | 400 | 0.7581 |
| 02:33 ET | 1556 | 0.7603 |
| 02:36 ET | 1886 | 0.7592 |
| 02:38 ET | 1844 | 0.75885 |
| 02:40 ET | 1546 | 0.7557 |
| 02:42 ET | 2076 | 0.75555 |
| 02:44 ET | 2334 | 0.75555 |
| 02:45 ET | 1425 | 0.75555 |
| 02:47 ET | 1400 | 0.7597 |
| 02:49 ET | 2300 | 0.7597 |
| 02:51 ET | 1728 | 0.7601 |
| 02:54 ET | 2200 | 0.7574 |
| 02:56 ET | 1000 | 0.75875 |
| 02:58 ET | 1400 | 0.7574 |
| 03:00 ET | 600 | 0.7601 |
| 03:02 ET | 1693 | 0.7597 |
| 03:03 ET | 2824 | 0.75555 |
| 03:05 ET | 2412 | 0.7556 |
| 03:07 ET | 4552 | 0.7511 |
| 03:09 ET | 1192 | 0.7511 |
| 03:12 ET | 310 | 0.7526 |
| 03:14 ET | 6446 | 0.7524 |
| 03:16 ET | 3676 | 0.7539 |
| 03:18 ET | 1729 | 0.7526 |
| 03:20 ET | 498 | 0.7526 |
| 03:21 ET | 1449 | 0.7525 |
| 03:23 ET | 941 | 0.7522 |
| 03:25 ET | 2243 | 0.751 |
| 03:27 ET | 1780 | 0.751 |
| 03:30 ET | 6351 | 0.7427 |
| 03:32 ET | 1100 | 0.741 |
| 03:34 ET | 1600 | 0.7411 |
| 03:36 ET | 2529 | 0.74 |
| 03:38 ET | 4903 | 0.74 |
| 03:39 ET | 4520 | 0.74 |
| 03:41 ET | 2998 | 0.7402 |
| 03:43 ET | 3543 | 0.7479 |
| 03:45 ET | 4460 | 0.7455 |
| 03:48 ET | 1000 | 0.7404 |
| 03:50 ET | 4370 | 0.745 |
| 03:52 ET | 21401 | 0.7428 |
| 03:54 ET | 57085 | 0.7428 |
| 03:56 ET | 13219 | 0.75 |
| 03:57 ET | 6380 | 0.75 |
| 03:59 ET | 16016 | 0.7233 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Allovir Inc | 83.2M | -0.4x | --- |
PMV Pharmaceuticals Inc | 83.3M | -1.2x | --- |
Connect Biopharma Holdings Ltd | 83.8M | -1.4x | --- |
Boundless Bio Inc | 86.1M | 0.0x | --- |
Serina Therapeutics Inc | 80.6M | -0.7x | --- |
Checkpoint Therapeutics Inc | 79.2M | -0.9x | --- |
Company Information
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Contact Information
- Headquarters
- 1100 Winter StreetWALTHAM, MA, United States 02451
- Phone
- 617-433-2605
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board
- David Hallal
- President, Chief Financial Officer, Director
- Vikas Sinha
- Chief Executive Officer, Director
- Diana Brainard
- Co-Founder, Chief Scientific Officer
- Ann Leen
- Chief Accounting Officer
- Brett Hagen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $83.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 115.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.77 |
EPS | $-1.65 |
Book Value | $1.28 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
